市场调查报告书
商品编码
1355829
药物发现市场中的人工智慧(AI)-按组件(软体、服务)、技术(机器学习{深度学习})、应用类型(目标识别)、治疗领域(肿瘤学)、最终用途(CRO)、全球预测, 2023-2032Artificial Intelligence (AI) in Drug Discovery Market-By Component (Software, Service), Technology (Machine learning {Deep Learning}), Application Type (Target Identification), Therapeutic Area (Oncology), End-use (CRO), Global Forecast, 2023-2032 |
在越来越多的跨产业合作和伙伴关係的推动下,药物发现市场中的全球人工智慧 (AI) 将从 2023 年到 2032 年以 30.1% 的复合年增长率成长。製药专业知识与人工智慧驱动技术的融合可实现更快、更有效率的药物发现过程。合作促进了人工智慧演算法与药物研究的整合,加速了潜在化合物的识别并缩短了开发时间。不同部门之间的协同作用促进了创新,推动了人工智慧在药物发现产业的发展。
举个例子,2023 年 10 月,Evozyn 透露完成了 8,100 万美元的 B 轮融资,致力于支持其人工智慧驱动的生成药物发现平台和产品开发工作的进展。这项进展是在 2023 年初与 NVIDIA 建立富有成效的合作关係之后推出的,在此期间,两家公司共同创建了一个能够设计治疗性蛋白质的创新人工智慧模型。
药物发现市场中的整体人工智慧根据组件、技术、应用、治疗领域、最终用途和地区进行分类。
服务部门可能在 2023 年至 2032 年期间获得可观的利益。药物发现服务中的人工智慧需求量很大,因为它们能够显着加快药物开发过程。人工智慧演算法可以分析大量资料集,预测潜在的候选药物,并以惊人的速度和精确度优化分子结构。这不仅缩短了研发时间,也降低了成本。随着对更快、更有效率的药物发现解决方案的需求,该领域对人工智慧服务的需求持续成长。
到 2032 年,药物发现解决方案和服务中的人工智慧可能会在临床前测试应用中遇到激增的需求,因为它们提高了准确性和效率。人工智慧驱动的演算法可以快速分析复杂的生物和化学资料,帮助识别有前途的候选药物并预测它们在临床前测试中的行为。这减少了对大量实验室实验的需求,加快了药物开发时间,并最终降低了成本,使得人工智慧在药物发现的临床前测试阶段不可或缺。
2023 年至 2032 年间,欧洲药物发现产业的人工智慧可能呈现显着的复合年增长率。欧洲拥有强大的製药业,并且正在大力投资人工智慧研究。根据 EFPIA 2022 年年度报告,欧洲研究型製药产业产值大幅成长,从 2000 年的 1,275 亿欧元成长到 2021 年的 3,000 亿欧元。同期为 909 亿欧元至 5,650 亿欧元。 2021年进口额达3,900亿欧元,贸易顺差达1,750亿欧元。
对创新的监管支援以及学术界、新创公司和老牌製药公司之间的合作伙伴关係促进了人工智慧的采用。此外,需要更有效率的药物开发流程来对抗 COVID-19 等疾病,这加速了整个欧洲地区对药物发现中人工智慧解决方案的需求。
Global Artificial Intelligence (AI) in Drug Discovery Market will expand at 30.1% CAGR from 2023 to 2032, driven by the growing number of cross-industry collaborations and partnerships. The convergence of pharmaceutical expertise with AI-driven technologies enables faster and more efficient drug discovery processes. Collaborations facilitate the integration of AI algorithms into drug research, accelerating the identification of potential compounds and reducing development timelines. This synergy between different sectors fuels innovation, driving the growth of the AI in drug discovery industry.
Quoting an instance, in October 2023, Evozyn revealed the completion of an $81 million Series B funding round dedicated to supporting the advancement of its generative AI-powered drug discovery platform and product development efforts. This development comes on the heels of a productive partnership with NVIDIA earlier in 2023, during which the two companies jointly created an innovative AI model capable of designing therapeutic proteins.
The overall AI in drug discovery market is categorized based on component, technology, application, therapeutic area, end-use, and region.
The services segment could garner commendable gains throughout 2023-2032. AI in drug discovery services is in high demand due to their ability to significantly expedite the drug development process. AI algorithms can analyze vast datasets, predict potential drug candidates, and optimize molecular structures with remarkable speed and precision. This not only reduces research and development timelines but also lowers costs. With the need for faster and more efficient drug discovery solutions, the demand for AI services in this sector continues to grow.
AI in drug discovery solutions and services could experience surging demand in preclinical testing applications by 2032 because they enhance accuracy and efficiency. AI-powered algorithms can swiftly analyze complex biological and chemical data, aiding in the identification of promising drug candidates and predicting their behavior in preclinical testing. This reduces the need for extensive laboratory experiments, accelerates the drug development timeline, and ultimately lowers costs, making AI indispensable in the preclinical testing phase of drug discovery.
Europe AI in drug discovery industry could exhibit noteworthy CAGR between 2023-2032. Europe boasts a strong pharmaceutical sector and is investing significantly in AI research. According to EFPIA's Annual Report for 2022, the research-based pharmaceutical industry in Europe has seen substantial growth in production value, rising from 127.5 billion euros in 2000 to 300 billion euros in 2021. Equally noteworthy is the remarkable increase in exports, which surged from 90.9 billion euros to 565 billion euros during the same timeframe. In 2021, imports accounted for 390 billion euros, resulting in a positive trade balance of 175 billion euros.
Regulatory support for innovation and partnerships between academia, startups, and established pharmaceutical companies fosters AI adoption. Additionally, the need for more efficient drug development processes to combat diseases like COVID-19 accelerates the demand for AI solutions in drug discovery across the European region.